CTDSPL Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population offering a loss-of-function model for the CTDSPL tumor suppressor gene. Derived from the Raji B lymphoblastoid cell line, this product enables interrogation of CTDSPL function in B lymphocyte biology. The polyclonal knockout populations are generated via CRISPR/Cas9-mediated gene disruption, providing a flexible tool for studying transcriptional regulation and signaling pathways relevant to B cell malignancies.
The Raji cell line is a human Burkitt’s lymphoma-derived B lymphoblastoid line that is positive for Epstein-Barr virus (EBV). It serves as a well-established model for antigen presentation and EBV infection studies. These suspension cells express key Notch pathway components, making them suitable for examining CTDSPL-mediated regulation in a B cell context. Raji cells are compatible with a range of assays including flow cytometry, western blotting, and transcriptomic analyses.
CTDSPL encodes a small C-terminal domain phosphatase that dephosphorylates RNA polymerase II CTD and the Notch1 intracellular domain (NICD), targeting NICD for degradation to inhibit Notch-mediated transcription of targets such as HES1. It functions as a negative regulator of transcription and tumor suppressor, activated downstream of TGF-beta signaling and silenced via DNA methylation in various cancers. CTDSPL interacts with NICD and RNA polymerase II holoenzyme, linking growth factor signaling to transcriptional repression and cell cycle control.
In the Raji B lymphoblastoid background, CTDSPL disruption allows investigation of its tumor-suppressive roles in B cell lymphomagenesis. The EBV-positive Raji cells exhibit active Notch signaling, and loss of CTDSPL is predicted to enhance NICD stability and downstream oncogenic transcription, modeling lymphoma progression. This polyclonal knockout population represents a heterogeneous pool of gene disruptions ideal for population-level functional analyses without clonal bias, suitable for studying apoptosis resistance and viral-host interactions.
These cells support applications such as RT-qPCR and western blotting for Notch target gene expression, co-immunoprecipitation for NICD interaction studies, and phospho-signaling analysis of RNA polymerase II CTD. Functional assays like apoptosis and proliferation profiling reveal the phenotypic impact of CTDSPL loss. The model is valuable for drug screening targeting Notch-dependent lymphomas and RNA-seq to uncover transcriptional networks. Researchers can assess responses to TGF-beta stimulation or EBV gene expression changes. For further information, contact Ascent Research.
